age \< 18 pregnant allergic to experimental drugs and patients have the following conditions: 1. hypercholesterolemia 2. hypertriglyceridemia 3. liver disease 4. renal disease 5. sjögren syndrome 6. pregnancy 7. lactation 8. depressive disorder 9. body mass index less than 18 points or higher than 25 points 10. contraindications for hormonal contraception or intrauterine device. 11. autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation 12. patients receiving anti-hcv treatment 13. permanent blindness in one eye 14. history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery 15. the competent physician considered it inappropriate to participate in the study 16. hiv infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/l 17. abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) \>1.5 × upper limit of normal or total bilirubin \> upper limit of normal (unless gilbert's disease with normal conjugated bilirubin) 18. any of the following laboratory abnormalities are present at baseline: * platelet count \<150×109/l * serum albumin ≤ 3.5 g/dl * inr ≥1.2 * cpk ≥ uln. 19. significant liver fibrosis as evidenced by fibrosis-4 (fib-4) score \>3.25 20. history of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)

age \< 18 pregnant allergic to experimental drugs and patients have the following conditions: 1. hypercholesterolemia 2. hypertriglyceridemia 3. liver disease 4. renal disease 5. sjögren syndrome 6. pregnancy 7. lactation 8. depressive disorder 9. body mass index less than 18 points or higher than 25 points 10. contraindications for hormonal contraception or intrauterine device. 11. autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation 12. patients receiving anti-hcv treatment 13. permanent blindness in one eye 14. history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery 15. the competent physician considered it inappropriate to participate in the study 16. hiv infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/l 17. abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) \>1.5 × upper limit of normal or total bilirubin \> upper limit of normal (unless gilbert's disease with normal conjugated bilirubin) 18. any of the following laboratory abnormalities are present at baseline: * platelet count \<150×109/l * serum albumin ≤ 3.5 g/dl * inr ≥1.2 * cpk ≥ uln. 19. significant liver fibrosis as evidenced by fibrosis-4 (fib-4) score \>3.25 20. history of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)

age < 18 pregnant allergic to experimental drugs and patients have the following conditions: hypercholesterolemia hypertriglyceridemia liver disease renal disease sjögren syndrome pregnancy lactation depressive disorder body mass index less than 18 points or higher than 25 points contraindications for hormonal contraception or intrauterine device. autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation patients receiving anti-hcv treatment permanent blindness in one eye history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery the competent physician considered it inappropriate to participate in the study hiv infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/l abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) >1.5 × upper limit of normal or total bilirubin > upper limit of normal (unless gilbert's disease with normal conjugated bilirubin) any of the following laboratory abnormalities are present at baseline: platelet count <150×109/l serum albumin ≤ 3.5 g/dl inr ≥1.2 cpk ≥ uln. significant liver fibrosis as evidenced by fibrosis-4 (fib-4) score >3.25 history of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)

age < 18 pregnant allergic to experimental drugs and patients have the following conditions: hypercholesterolemia hypertriglyceridemia liver disease renal disease sjögren syndrome pregnancy lactation depressive disorder body mass index less than 18 points or higher than 25 points contraindications for hormonal contraception or intrauterine device. autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation patients receiving anti-hcv treatment permanent blindness in one eye history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery the competent physician considered it inappropriate to participate in the study hiv infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/l abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) >1.5 × upper limit of normal or total bilirubin > upper limit of normal (unless gilbert's disease with normal conjugated bilirubin) any of the following laboratory abnormalities are present at baseline: platelet count <150×109/l serum albumin ≤ 3.5 g/dl inr ≥1.2 cpk ≥ uln. significant liver fibrosis as evidenced by fibrosis-4 (fib-4) score >3.25 history of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)

age < 18 pregnant allergic to experimental drugs and patients have the following conditions: 1. hypercholesterolemia 2. hypertriglyceridemia 3. liver disease 4. renal disease 5. sjögren syndrome 6. pregnancy 7. lactation 8. depressive disorder 9. body mass index less than 18 points or higher than 25 points 10. contraindications for hormonal contraception or intrauterine device. 11. autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation 12. patients receiving anti-hcv treatment 13. permanent blindness in one eye 14. history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery 15. the competent physician considered it inappropriate to participate in the study 16. hiv infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/l 17. abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) >1.5 × upper limit of normal or total bilirubin > upper limit of normal (unless gilbert's disease with normal conjugated bilirubin) 18. any of the following laboratory abnormalities are present at baseline: - platelet count <150×109/l - serum albumin ≤ 3.5 g/dl - inr ≥1.2 - cpk ≥ uln. 19. significant liver fibrosis as evidenced by fibrosis-4 (fib-4) score >3.25 20. history of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)

age < 18 pregnant allergic to experimental drugs and patients have the following conditions: 1. hypercholesterolemia 2. hypertriglyceridemia 3. liver disease 4. renal disease 5. sjögren syndrome 6. pregnancy 7. lactation 8. depressive disorder 9. body mass index less than 18 points or higher than 25 points 10. contraindications for hormonal contraception or intrauterine device. 11. autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation 12. patients receiving anti-hcv treatment 13. permanent blindness in one eye 14. history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery 15. the competent physician considered it inappropriate to participate in the study 16. hiv infection or other immunodeficiency or with an absolute neutrophil count ≤1.0 × 109/l 17. abnormal liver biochemistry (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase) >1.5 × upper limit of normal or total bilirubin > upper limit of normal (unless gilbert's disease with normal conjugated bilirubin) 18. any of the following laboratory abnormalities are present at baseline: - platelet count <150×109/l - serum albumin ≤ 3.5 g/dl - inr ≥1.2 - cpk ≥ uln. 19. significant liver fibrosis as evidenced by fibrosis-4 (fib-4) score >3.25 20. history of hypersensitivity to retinoic acid or any of its excipients or the class of neutrophil elastase inhibitors known hypersensitivity to medications used in the study procedures (e.g. midazolam, fentanyl, and lidocaine for bronchoscopy)